Close Menu

NEW YORK – Bio-Techne on Wednesday said that the General Services Administration (GSA) has awarded a 10-year reimbursement contract to its Exosome Diagnostics laboratory for the ExoDx Prostate (EPI) test.

The contract took effect today, providing 9 million additional men access to the urine-based genomic EPI test for early detection of prostate cancer, the firm said.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Wall Street Journal reports on the struggle to meet the demand for rapid COVID-19 testing.

The Newsroom reports New Zealand is using genomics to trace the origins of its new coronavirus outbreak.

In Nature this week: researchers in Canada sequence the genome of the black mustard plant Brassica nigra, and more.

According to Bloomberg, Moderna has a $1.5 billion vaccine deal with the US to provide 100 million doses.